Elisabeth Oelmann

1.2k total citations
31 papers, 773 citations indexed

About

Elisabeth Oelmann is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Elisabeth Oelmann has authored 31 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Oncology and 11 papers in Immunology. Recurrent topics in Elisabeth Oelmann's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Immune Cell Function and Interaction (6 papers) and Advanced Breast Cancer Therapies (4 papers). Elisabeth Oelmann is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Immune Cell Function and Interaction (6 papers) and Advanced Breast Cancer Therapies (4 papers). Elisabeth Oelmann collaborates with scholars based in Germany, United Kingdom and United States. Elisabeth Oelmann's co-authors include Wolfgang E. Berdel, B. Reufi, Hubert Serve, Wendy Burke, Udai Banerji, D Oberberg, Harald Stein, Hermann Herbst, Lynda Grinsted and Éric Raymond and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Elisabeth Oelmann

29 papers receiving 757 citations

Peers

Elisabeth Oelmann
Charlotte Rorsman Sweden
Catherine Gaudin France
Greg Riggins United States
Archontoula Stoffel United States
Katherine Chung United States
M Fukumoto Japan
Georgina Berrozpe United States
W Zhang United States
Kabir A. Khan United Kingdom
Patrik Georgii‐Hemming Sweden
Charlotte Rorsman Sweden
Elisabeth Oelmann
Citations per year, relative to Elisabeth Oelmann Elisabeth Oelmann (= 1×) peers Charlotte Rorsman

Countries citing papers authored by Elisabeth Oelmann

Since Specialization
Citations

This map shows the geographic impact of Elisabeth Oelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Oelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Oelmann more than expected).

Fields of papers citing papers by Elisabeth Oelmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Oelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Oelmann. The network helps show where Elisabeth Oelmann may publish in the future.

Co-authorship network of co-authors of Elisabeth Oelmann

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Oelmann. A scholar is included among the top collaborators of Elisabeth Oelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Oelmann. Elisabeth Oelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Blagden, Sarah P., Stefan N. Symeonides, In Hwa Um, et al.. (2023). Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study. Molecular Cancer Therapeutics. 22(12_Supplement). C032–C032.
3.
Pacey, Simon, Nimish Shah, Barry R. Davies, et al.. (2018). A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).. Journal of Clinical Oncology. 36(15_suppl). 5081–5081. 3 indexed citations
4.
Pacey, Simon, Nimish Shah, Ola Bratt, et al.. (2017). CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).. Journal of Clinical Oncology. 35(6_suppl). 97–97.
5.
Basu, Bristi, Emma Dean, M. Puglisi, et al.. (2015). First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research. 21(15). 3412–3419. 102 indexed citations
6.
Oelmann, Elisabeth, Harald Stein, Wolfgang E. Berdel, & Hermann Herbst. (2015). Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma. PLoS ONE. 10(9). e0138747–e0138747. 13 indexed citations
7.
Naing, Aung, Carol Aghajanian, Éric Raymond, et al.. (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. British Journal of Cancer. 107(7). 1093–1099. 107 indexed citations
8.
Banerji, Udai, Emma Dean, Michael V. Gonzalez, et al.. (2012). First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3004–3004. 27 indexed citations
9.
Banerji, Udai, Carol Aghajanian, Éric Raymond, et al.. (2011). First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.. Journal of Clinical Oncology. 29(15_suppl). 3096–3096. 17 indexed citations
10.
Berdel, Wolfgang E., et al.. (2005). Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells. Annals of Hematology. 84(12). 771–773. 4 indexed citations
11.
12.
Oelmann, Elisabeth, M. Thomas, Hubert Serve, et al.. (2002). Early Tandem High-Dose Ifosfamide, Carboplatin, Etoposide Therapy with Stem Cell Rescue for Small-Cell Lung Cancer: Brief Report on the Results of a Phase-I/II Trial. Oncology. 63(3). 248–253. 4 indexed citations
13.
14.
Padró, Teresa, P. Koch, Elisabeth Oelmann, et al.. (2002). Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma. Oncology Reports. 9(3). 525–7. 18 indexed citations
15.
Oelmann, Elisabeth, Hubert Serve, B. Reufi, et al.. (1997). Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. International Journal of Cancer. 71(6). 1066–1076. 42 indexed citations
16.
Papadimitriou, Christos, et al.. (1995). Immunomagnetic Selection of CD34+ Cells from Fresh Peripheral Blood Mononuclear Cell Preparations Using Two Different Separation Techniques. Journal of Hematotherapy. 4(6). 539–544. 17 indexed citations
17.
Topp, Max S., Elisabeth Oelmann, B Koehler, et al.. (1995). Antiproliferative Effect of Human Interleukin-4 in Human Cancer Cell Lines: Studies on the Mechanism. Leukemia & lymphoma. 19(3-4). 319–328. 9 indexed citations
18.
Topp, Max S., Hubert Serve, Elisabeth Oelmann, et al.. (1995). Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. European Journal of Cancer. 31(13-14). 2371–2378. 27 indexed citations
19.
Oelmann, Elisabeth, B. Reufi, Constantine S. Papadimitriou, et al.. (1994). INTERLEUKIN-1 RECEPTOR ANTAGONIST INHIBITS GROWTH MODULATION OF HUMAN TUMOR-CELL LINES BY INTERLEUKIN-1 IN-VITRO. International Journal of Oncology. 4(3). 555–8. 1 indexed citations
20.
Foss, Hans‐Dieter, Hermann Herbst, Elisabeth Oelmann, et al.. (1993). Lymphotoxin, tumour necrosis factor and interleukin‐6 gene transcripts are present in Hodgkin and Reed‐Sternberg cells of most Hodgkin's disease cases. British Journal of Haematology. 84(4). 627–635. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte Rorsman Breakdown of academic impact, for papers by Catherine Gaudin Breakdown of academic impact, for papers by Greg Riggins Breakdown of academic impact, for papers by Archontoula Stoffel Breakdown of academic impact, for papers by Katherine Chung Breakdown of academic impact, for papers by M Fukumoto Breakdown of academic impact, for papers by Georgina Berrozpe Breakdown of academic impact, for papers by W Zhang Breakdown of academic impact, for papers by Kabir A. Khan Breakdown of academic impact, for papers by Patrik Georgii‐Hemming
Rankless by CCL
2026